Catalent (CTLT) 10-Q 14 Feb 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2023	Jan. 31, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-36587
Entity Registrant Name	Catalent, Inc.
Entity Incorporation, State or Country Code	DE
Entity Address, State or Province	NJ
Entity Tax Identification Number	20-8737688
Entity Address, Address Line One	14 Schoolhouse Road
Entity Address, City or Town	Somerset,
Entity Address, Postal Zip Code	08873
City Area Code	(732)
Local Phone Number	537-6200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	CTLT
Security Exchange Name	NYSE
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001596783
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding (shares)		180,737,675

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue		$ 1,024	$ 1,149	$ 2,006	$ 2,171
Cost of sales		853	762	1,666	1,526
Gross margin		171	387	340	645
Selling, general, and administrative expenses		250	226	455	422
Goodwill, Impairment Loss		(2)	0	(687)	0
Other Cost and Expense, Operating		35	23	36	25
Operating earnings		(112)	138	(838)	198
Interest expense, net		66	47	124	79
Other (income)/expense, net	[1]	4	(23)	17	2
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total		(182)	114	(979)	117
Income tax expense		24	33	(14)	36
Net earnings/(loss)		$ (206)	$ 81	$ (965)	$ 81
Earnings Per Share, Basic		$ (1.13)	$ 0.45	$ (5.31)	$ 0.45
Earnings Per Share, Diluted		$ (1.13)	$ 0.44	$ (5.31)	$ 0.45
[1]Other expense, net during the three months ended December 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Other comprehensive income/(loss), net of tax
Net earnings/(loss)	$ (206)	$ 81	$ (965)	$ 81	$ (965)
Foreign currency translation adjustments	37	118	(2)	(17)
Pension and other post-retirement adjustments	4	0	4	0
Available for sale investments	0	1	0	2
Net change in derivatives and hedges, net of tax	(7)	0	(2)	14
Other comprehensive income/(loss), net of tax	34	119	0	(1)	$ 0
Comprehensive income/(loss)	$ (172)	$ 200	$ (965)	$ 80

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 229	$ 280
Trade receivables, net	843	1,002
Inventories	775	777
Prepaid expenses and other	723	633
Total current assets	2,570	2,692
Property, plant, and equipment, net	3,777	3,682
Other assets:
Goodwill	2,351	3,039
Other intangibles, net	911	980
Deferred Income Tax Assets, Net	55	55
Other Assets, Noncurrent	324	329
Total assets	9,988	10,777
Current Liabilities:
Debt, Current	46	536
Accounts payable	407	424
Other accrued liabilities	583	570
Total current liabilities	1,036	1,530
Long-term obligations, less current portion	4,959	4,313
Pension liability	101	100
Deferred Income Taxes	50	76
Other liabilities	155	147
Total liabilities	$ 6,301	$ 6,166
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Value, Outstanding	$ 2	$ 2
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	4,742	4,701
Accumulated deficit	(703)	262
Accumulated other comprehensive income/(loss)	(354)	(354)
Total shareholders' equity	3,687	4,611
Total liabilities, redeemable preferred stock, and shareholders’ equity	$ 9,988	$ 10,777
Common stock, shares issued (shares)	181,000,000	180,000,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	181,000,000	180,000,000
Common Stock, Shares, Outstanding	180,000,000	179,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Accounts Receivable, Allowance for Credit Loss, Current	$ 42	$ 46
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 1,756	$ 1,596

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholder's Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares, Outstanding		179,302,000,000
Beginning Balance at Jun. 30, 2022	$ 4,775	$ 2	$ 4,649	$ 518	$ (394)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	29		29
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	7		7
Non-qualified stock	1		(1)
Net earnings/(loss)	81			81
Other comprehensive income/(loss), net of tax	(1)				(1)
Ending Balance at Dec. 31, 2022	4,912	$ 2	4,686	619	(395)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		686,000,000
Common Stock, Shares, Outstanding		179,901,000,000
Beginning Balance at Sep. 30, 2022	4,700	$ 2	4,674	538	(514)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Stock Options Exercised	0	0	0
Stock-based compensation	10		10
Cash paid, in lieu of equity, for tax withholding	(2)		(2)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	4		4
Net earnings/(loss)	81			81
Other comprehensive income/(loss), net of tax	119				119
Ending Balance at Dec. 31, 2022	$ 4,912	$ 2	4,686	619	(395)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuances related to stock-based compensation		87,000,000
Common Stock, Shares, Outstanding		179,988,000,000
Common Stock, Shares, Outstanding	179,000,000	180,273,000,000
Beginning Balance at Jun. 30, 2023	$ 4,611	$ 2	4,701	262	(354)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings/(loss)	(965)
Other comprehensive income/(loss), net of tax	0
Ending Balance at Dec. 31, 2023	3,687	$ 2	4,742	(703)	(354)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares, Outstanding		180,521,000,000
Beginning Balance at Sep. 30, 2023	3,841	$ 2	4,724	(497)	(388)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity offering, sale of common stock,		0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0
Stock-based compensation	16		16
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	2		2
Net earnings/(loss)	(206)			(206)
Other comprehensive income/(loss), net of tax	34				34
Ending Balance at Dec. 31, 2023	$ 3,687	$ 2	$ 4,742	$ (703)	$ (354)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		147,000,000
Common Stock, Shares, Outstanding	180,000,000	180,668,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings/(loss)	$ (965)	$ 81
Adjustments to reconcile earnings/(loss) from operations to net cash from operations:
Depreciation and amortization	233	202
Goodwill, Impairment Loss	687	0
Non-cash foreign currency transaction (gain)/loss, net	11	1
Total restructuring costs	7	7
Amortization and write-off of debt financing costs	6	4
Asset impairments charges and (gain)/loss on sale of assets	14	(1)
Share issuances related to stock-based compensation	35	29
Provision/(benefit) for deferred income taxes	(27)	13
Provision for bad debts and inventory	44	67
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables	165	148
Decrease/(increase) in inventories	(46)	(180)
Increase/(decrease) in accounts payable	(40)	(68)
Other assets/accrued liabilities, net — current and non-current	(85)	(181)
Net Cash Provided by (Used in) Operating Activities, Total	42	122
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets	(178)	(317)
Proceeds from Sale and Maturity of Marketable Securities	0	61
Proceeds from Sale of Property, Plant, and Equipment	1	7
Payment for acquisitions, net of cash acquired	0	(474)
Payments to Acquire Investments		(1)
Proceeds from Sale and Maturity of Other Investments	(2)
Net cash (used in) investing activities	(179)	(724)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in other borrowings	815	625
Payments related to long-term obligations	(722)	(32)
Payments of Debt Issuance Costs	(16)	(4)
Proceeds from (Repurchase of) Equity [Abstract]
Proceeds from Stock Options Exercised	1	1
Proceeds from (Payments for) Other Financing Activities	6	7
Net cash (used in)/provided by financing activities	84	597
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	2	(2)
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS	(51)	(7)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	229	442
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	280
CASH AND EQUIVALENTS AT END OF PERIOD	229
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid	112	83
Income taxes paid, net	31	38
Capital Expenditures Incurred but Not yet Paid	$ 21	$ 13

Accounting Changes and Error Co

Accounting Changes and Error Corrections - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
REVISIONS OF PREVIOUSLY-ISSUED FINANCIAL STATEMENTS [Text Block]	REVISIONS OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS As described in the Amended Fiscal 2022 10-K, in preparing the consolidated financial statements for the three and nine months ended March 31, 2023, the Company identified a $26 million error related to the over-recognition of revenue in the consolidated financial statements it issued with respect to its fiscal year ended June 30, 2022. This error resulted from the misapplication of the contract modification guidance in accordance with ASC 606, Revenue from Contracts with Customers, related to one of the Company’s customer arrangements. The Company assessed the materiality of the error both quantitatively and qualitatively and determined this error to be immaterial to those consolidated financial statements. However, the Company concluded that the effect of correcting the error in the quarter ended March 31, 2023 would materially misstate the Company’s unaudited consolidated financial statements for the three and nine months ended March 31, 2023 and, accordingly, determined that it was necessary to revise the consolidated financial statements it previously issued with respect to the fiscal year ended June 30, 2022. The following tables reflect the impact of this revision on the Company’s consolidated balance sheet as of June 30, 2022: Consolidated Balance Sheet June 30, 2022 (Dollars in millions) As Previously Reported Adjustment As Revised Prepaid expenses and other $ 625 $ 1 $ 626 Total current assets 2,916 1 2,917 Total assets 10,507 1 10,508 Other accrued liabilities 620 26 646 Total current liabilities 1,072 26 1,098 Deferred income taxes 202 (5) 197 Total liabilities 5,712 21 5,733 Retained earnings 538 (20) 518 Total shareholders' equity 4,795 (20) 4,775 Total liabilities and shareholders' equity $ 10,507 $ 1 10,508
Other Accrued Liabilities		$ 646

Business Combinations

Business Combinations	3 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS COMBINATIONS

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2023
Goodwill Disclosure [Abstract]
Goodwill	GOODWILL The following table summarizes the changes between June 30, 2023 and December 31, 2023 in the carrying amount of goodwill in total and by segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2023 $ 1,563 $ 1,476 $ 3,039 Foreign currency translation adjustments 2 (3) (1) Impairment (1) (392) (295) (687) Balance at December 31, 2023 $ 1,173 $ 1,178 $ 2,351 (1) Represents gross impairment charges in the period. Accumulated goodwill impairment charges amount to $897 million. Goodwill Impairment Charges As a result of the Consumer Health reporting unit's underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, the Company assessed the current and future economic outlook as of September 30, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified indicators for impairment of the goodwill previously recorded for two of its reporting units. The evaluation began with a qualitative assessment of the Company's Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of $687 million with respect to the Consumer Health and Biomodalities reporting units. While the Company believes the assumptions it used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to the conclusion that an additional impairment was appropriate.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	LOSS) EARNINGS PER SHARE The Company computes (loss) earnings per share of the Company’s common stock, par value $0.01 (the “Common Stock”) using the treasury stock method. Diluted net (loss) earnings per share is computed using the weighted average number of shares of Common Stock outstanding plus the weighted average number of shares of Common Stock that would be issued assuming exercise or conversion of all potentially dilutive instruments. Dilutive securities having an anti-dilutive effect on diluted net earnings per share are excluded from the calculation. The dilutive effect of the securities that are issuable under the Company’s equity incentive plans are reflected in diluted earnings per share by application of the treasury stock method. The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three and six months ended December 31, 2023 and 2022, respectively, are as follows: Three Months Ended Six Months Ended (In millions except per share data) 2023 2022 2023 2022 Net (loss) earnings $ (206) $ 81 $ (965) $ 81 Weighted average shares outstanding - basic 182 181 181 180 Weighted average dilutive securities issuable - stock plans — — — 1 Weighted average shares outstanding - diluted 182 181 181 181 (Loss) earnings per share: Basic $ (1.13) $ 0.45 $ (5.31) $ 0.45 Diluted $ (1.13) $ 0.44 $ (5.31) $ 0.45 Shares with an antidilutive effect on the weighted average shares outstanding for the three and six months ended December 31, 2023 and 2022 were not material.

Other (Income)_ Expense, Net

Other (Income)/ Expense, Net	6 Months Ended
	Dec. 31, 2023
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure [Text Block]	OTHER EXPENSE (INCOME), NET The components of other expense (income), net for the three and six months ended December 31, 2023 and 2022 are as follows: Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency losses (gains) (1) $ 4 $ (25) 15 (1) Other — 2 2 3 Total other expense (income), net $ 4 $ (23) $ 17 $ 2 (1) Foreign currency remeasurement gains/losses include both cash and non-cash transactions.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	6 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in operations outside the U.S. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated exposure from its investments in its European operations by denominating a portion of its debt in euros. At December 31, 2023, the Company had euro-denominated debt outstanding of $910 million (U.S. dollar equivalent), which is designated and qualifies as a hedge against its net investment in its European operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of translation gains or losses are reported in accumulated other comprehensive loss as part of the cumulative translation adjustment. The following table summarizes net investment hedge activity during the three and six months ended December 31, 2023 and 2022. Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Unrealized foreign exchange loss within other comprehensive income $ (38) $ (85) $ (6) $ (4) The net accumulated gain on the instrument designated as a hedge as of December 31, 2023 within other comprehensive loss was approximately $91 million. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity to which the gains and losses relate is either sold or substantially liquidated. Interest-Rate Swap In February 2021, the Company entered into an interest-rate swap agreement with Bank of America N.A. (the “2021 Rate Swap”) as a hedge against the economic effect of a portion of the variable interest obligation associated with its Term B-3 Loans. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the Term B-3 Loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on $500 million of the Term B-3 Loans is now effectively fixed at 0.9985%. To conform with the adoption of Topic 848, Reference Rate Reform and the Eighth Amendment , the Company amended the 2021 Rate Swap in June 2023 (the “2023 Rate Swap”). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on $500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized loss recorded in stockholder's equity related to the mark-to-market change in the 2021 Rate Swap during the three and six months ended December 31, 2023 was $2 million. A summary of the estimated fair value of the 2021 Rate Swap reported in the consolidated balance sheets is stated in the table below: December 31, 2023 June 30, 2023 (Dollars in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 59 Other long-term assets $ 62

Fair Value Measures and Disclos

Fair Value Measures and Disclosures	6 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures	FAIR VALUE MEASUREMENTS ASC 820, Fair Value Measurement, defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at December 31, 2023 and June 30, 2023: (Dollars in millions) Basis of Fair Value Measurement December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 59 $ — $ 59 $ — Trading securities 5 5 — — June 30, 2023 Assets: Interest-rate swap $ 62 $ — $ 62 $ — Trading securities 1 1 — — The fair value of the 2021 Rate Swap was determined, and the fair value of the 2023 Rate Swap will be determined, at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-lived assets, goodwill, and other intangible assets are subject to non-recurring fair value measurement for the evaluation of potential impairment. T

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes . Generally, fluctuations in the effective tax rate are due to changes in relative amounts of U.S. and non-U.S. pretax income, the tax impact of special items, and other discrete tax items. Discrete items include, but are not limited to, changes in non-U.S. statutory tax rates, amortization of certain assets, changes in the Company’s reserve for uncertain tax positions, and tax impact of certain equity compensation. In the normal course of business, the Company is subject to examination by taxing authorities around the world. The Company is presently under audit in select jurisdictions in the United States and in Europe, but no material impact is expected to the financial results once these audits are completed. ASC 740 provides guidance for the accounting of uncertain income tax positions recognized in the Company's tax filings. This guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that, based on technical merits, the position will be sustained upon examination, including resolution of any related appeal or litigation process. As of December 31, 2023 and June 30, 2023, the Company’s reserve against uncertain income tax positions remained substantially unchanged at $4 million. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense. The Company recorded a provision for income taxes for the three months ended December 31, 2023 of $24 million relative to loss before income taxes of $182 million. The Company recorded a provision for income taxes for the three months ended December 31, 2022 of $33 million relative to earnings before income taxes of $114 million. The income tax expense for the quarter is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses. The quarterly provision was also impacted by the geographic distribution of the Company's pretax loss resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item. The Company recorded a benefit for income taxes for the six months ended December 31, 2023 of $14 million relative to loss before income taxes of $979 million. The Company recorded a provision for income taxes for the six months ended December 31, 2022 of $36 million relative to earnings before income taxes of $117 million. The income tax benefit for the period is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses.

Employee Retirement Benefit Pla

Employee Retirement Benefit Plans	6 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Retirement Benefit Plans	EMPLOYEE RETIREMENT BENEFIT PLANS Components of the Company’s net periodic benefit costs are as follows: Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1 $ 1 $ 2 $ 2 Other operating expense: Settlement charges 3 — 3 — Other expense, net: Interest cost 2 2 5 4 Expected return on plan assets (2) (2) (4) (4) Amortization (1) 1 — 1 — Net amount recognized $ 5 $ 1 $ 7 $ 2 (1) Amount represents the amortization of unrecognized actuarial losses. As previously disclosed, the Company notified the trustees of a multi-employer pension plan of its withdrawal from participation in such plan in fiscal 2012. The actuarial review process administered by the plan trustees ended in fiscal 2015. For the three months ended December 31, 2023, the Company decided to withdraw its participation from a multi-employer pension plan as a result of recent restructuring activities in its Pharma and Consumer Health segment. The liabilities reported reflect the present value of the Company’s expected future long-term obligations. The estimated discounted value of the projected contributions related to such plans was $44 million as of December 31, 2023 and $38 million as of June 30, 2023, and is included within pension liability on the consolidated balance sheets. The annual cash impact associated with the Company’s obligations in such plan is approximately $2 million. The Company is in the process of terminating the U.S. pension plan and will settle with its participants either in a lump sum payout or through the purchase of an annuity contract, dependent upon the participant’s selection of payment. The Company will seek to purchase nonparticipating annuities for participants who do not elect lump sum payouts. Participants who elected a lump sum payout were settled in the three months ended December 31, 2023. The $7 million of lump sum payments were made with cash from the assets of the qualified pension plan.

Equity and Accumulated Other Co

Equity and Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Equity, Redeemable Preferred Stock and Accumulated Other Comprehensive Loss	EQUITY AND ACCUMULATED OTHER COMPREHENSIVE LOSS Description of Capital Stock The Company is authorized to issue 1.00 billion shares of its Common Stock and 100 million shares of preferred stock, par value $0.01 per share. In accordance with the Company’s amended and restated certificate of incorporation, each share of Common Stock has one vote, and the Common Stock votes together as a single class. Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the three and six months ended December 31, 2023 and 2022 are presented below. Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency translation adjustments: Net investment hedge $ (38) $ (85) $ (6) $ (4) Long-term intercompany loans 14 31 (2) (10) Translation adjustments 73 155 8 (5) Total foreign currency translation adjustment, pretax 49 101 — (19) Tax (benefit) expense 12 (17) 2 (2) Total foreign currency translation adjustment, net of tax $ 37 $ 118 $ (2) $ (17) Net change in derivatives and hedges: Net gain recognized during the period $ (8) $ — $ (2) $ 18 Total derivatives and hedges, pretax (8) — (2) 18 Tax (benefit) expense (1) — — 4 Net change in derivatives and hedges, net of tax $ (7) $ — $ (2) $ 14 Net change in minimum pension liability: Net gain recognized during the period $ 3 $ — $ 3 $ — Total pension liability, pretax 3 — 3 — Tax benefit (1) — (1) — Net change in minimum pension liability, net of tax $ 4 $ — $ 4 $ — Net change in marketable securities: Net gain recognized during the period $ — $ 1 $ — $ 1 Amounts reclassified from accumulated other — 1 — 2 Net change in marketable securities, pretax — 2 — 3 Tax expense — 1 — 1 Net change in marketable securities, net of tax $ — $ 1 $ — $ 2 For the three months ended December 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Other Total Balance at September 30, 2023 $ (385) $ (52) $ 50 $ (1) $ (388) Other comprehensive income (loss) before 37 — (7) — 30 Amounts reclassified from accumulated other — 4 — — 4 Net current period other comprehensive income (loss) 37 4 (7) — 34 Balance at December 31, 2023 $ (348) $ (48) $ 43 $ (1) $ (354) (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at September 30, 2022 $ (513) $ (38) $ 41 $ (3) $ (1) $ (514) Other comprehensive income before 118 — — — — 118 Amounts reclassified from accumulated other — — — 1 — 1 Net current period other comprehensive income 118 — — 1 — 119 Balance at December 31, 2022 $ (395) $ (38) $ 41 $ (2) $ (1) $ (395)

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. City of Warwick Retirement System Class Action In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al. , No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, “the Warwick Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the " Warwick Complaint"), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the “Class Period”). The Warwick Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Company’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal controls over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. The Company believes that the Warwick Defendants have defenses to the allegations and claims set forth in the complaint and filed a motion to dismiss the Warwick Complaint on November 15, 2023. The plaintiffs filed their opposition to the Company's motion to dismiss on January 12, 2024, and the Company's reply to the plaintiffs' opposition is due February 15, 2024. Husty Derivative Claim In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al. , No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company's board of directors, (the “ Husty Defendants ” ), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. The Company believes that the Husty Defendants have defenses to the allegations and claims set forth in the complaint and, once all Husty Defendants are properly served with the complaint, intends to vigorously defend the Husty Defendants against such allegations. Brown Derivative Claim In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al. , Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company's board of directors (the “ Brown Defendants ” ) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On November 8, 2023, the court entered a stipulation between the parties extending the Brown Defendants’ time to respond to the complaint until January 19, 2024. The Company believes that the Brown Defendants have defenses to the allegations and claims set forth in the complaint and intends to vigorously defend the Brown Defendants against such allegations. Subpoenas and Requests for Information From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation. Fire at Biologics Facility

Segment Information

Segment Information	6 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company evaluates the performance of its segments based on segment earnings before other (expense) income, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (“Segment EBITDA”). Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies. The following tables include Segment EBITDA for each of the Company's current reportable segments during the three and six months ended December 31, 2023 and 2022: (Dollars in millions) Three Months Ended Six Months Ended 2023 2022 2023 2022 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 38 $ 181 $ 87 $ 294 Pharma and Consumer Health 126 135 227 243 Sub-Total $ 164 $ 316 $ 314 $ 537 Reconciling items to net earnings Unallocated costs (1) (159) (52) (936) (139) Depreciation and amortization (121) (103) (233) (202) Interest expense, net (66) (47) (124) (79) Income tax (expense) benefit (24) (33) 14 (36) Net (loss) earnings $ (206) $ 81 $ (965) $ 81 (1) Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Three Months Ended December 31, Six Months Ended 2023 2022 2023 2022 Impairment charges and gain/loss on sale of assets (a) $ (15) $ (1) $ (14) $ 1 Stock-based compensation (16) (10) (35) (29) Restructuring and other special items (b) (83) (33) (106) (42) Goodwill impairment adjustments (charges) (c) 2 — (687) — Pension settlement charges (3) — (3) — Other (expense) income, net (d) (4) 23 (17) (2) Unallocated corporate costs, net (40) (31) (74) (67) Total unallocated costs $ (159) $ (52) $ (936) $ (139) (a) Impairment charges and gain/loss on sale of assets for the three and six months ended December 31, 2023 includes fixed asset impairment charges associated with equipment for a product with significant decline demand in the Company's Biologics segment. (b) Restructuring and other special items during the three months ended December 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. Restructuring and other special items during the three months ended December 31, 2022 include (i) restructuring charges associated with our plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with our Metrics acquisition. Restructuring and other special items for the six months ended December 31, 2022 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. (c) Goodwill impairment charges during the six months ended December 31, 2023 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements. (d) Other expense, net during the three months ended December 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains. The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) December 31, June 30, Assets: Biologics $ 5,363 $ 5,746 Pharma and Consumer Health 4,517 4,867 Corporate and eliminations 108 164 Total assets $ 9,988 $ 10,777

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	6 Months Ended
	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental balance sheet information at December 31, 2023 and June 30, 2023 is detailed in the following tables. Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) December 31, June 30, Raw materials and supplies $ 793 $ 781 Work-in-process 200 186 Total inventories, gross 993 967 Inventory cost adjustment (218) (190) Total inventories $ 775 $ 777 Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) December 31, June 30, Prepaid expenses $ 58 $ 53 Short-term contract assets 478 399 Spare parts supplies 27 24 Prepaid income tax 75 77 Non-U.S. value-added tax 45 38 Other current assets 40 42 Total prepaid expenses and other $ 723 $ 633 Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) December 31, June 30, Contract liabilities $ 214 $ 167 Accrued employee-related expenses 136 160 Accrued expenses 141 134 Operating lease liabilities 9 11 Restructuring accrual 16 19 Accrued interest 39 35 Accrued income tax 28 44 Total other accrued liabilities $ 583 $ 570 Allowance for credit losses The rollforward of allowance for credit losses for the six months ended December 31, 2023 is as follows: Allowance for credit losses (Dollars in millions) Balance, June 30, 2023 $ 46 Charges (Credits) (4) Balance, December 31, 2023 $ 42

Subsequent Events (Notes)

Subsequent Events (Notes)	6 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events [Text Block]	17. SUBSEQUENT EVENTS Entry Into an Agreement and Plan of Merger On February 5, 2024, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Creek Parent, Inc. (“Parent”), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (“Novo Holdings”), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (the “DGCL”), Merger Sub will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of common stock of the Company. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the “Company Common Stock,” and each, a “Share”) that is issued and outstanding immediately prior to the Effective Time (other than any Shares held by (i) the Company, Parent or Merger Sub or any other direct or indirect wholly owned subsidiary of the Company or Parent immediately prior to the Effective Time, or (ii) a holder who has not voted in favor of the adoption of the Merger Agreement and is entitled to demand and properly demands appraisal of such Shares under the DGCL), will be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the “Merger Consideration”). The transaction values the Company at $16.5 billion on an enterprise value basis. Consummation of the Merger is subject to customary closing conditions, including approval of the Merger by the Company’s stockholders (which has not been obtained at this stage). Further conditions include (i) receipt of certain governmental waivers, consents, clearances, decisions, declarations, approvals, and expirations of applicable waiting periods, including the expiration or early termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to (A) the Merger and (B) the sale of three of the Company’s fill-finish sites (which are located in Anagni, Italy, Bloomington, Indiana USA, and Brussels, Belgium) and related assets from Novo Holdings to Novo Nordisk A/S (“Novo Nordisk”), of which Novo Holdings is the controlling shareholder (the “Carve-Out”), and (ii) the absence of any order, injunction or law prohibiting the Merger or the Carve-Out, in each case, without a Burdensome Condition (as defined in the Merger Agreement). Parent’s and Merger Sub’s obligations to close the Merger are also conditioned upon the absence of a Material Adverse Effect (as defined in the Merger Agreement) on the Company.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( “U.S. GAAP ” ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024. The consolidated balance sheet at June 30, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023 filed with the Securities and Exchange Commission (the “SEC”) on December 8, 2023. Reportable Segments Set forth below is a summary description of the Company's two current operating and reportable segments. Biologics—The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA ("pDNA"); induced pluripotent stem cells (" Pharma and Consumer Health—The Pharma and Consumer Health segment comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the United States (“U.S.”) into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary.
Depreciation, Depletion, and Amortization	Depreciation Depreciation expense was $88 million and $69 million for the three months ended December 31, 2023 and 2022, respectively. Depreciation expense was $166 million and $135 million for the six months ended December 31, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. Amortization
Research and Development Costs	Research and Development Costs

Revenue Recognition (Tables)

Revenue Recognition (Tables) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,024	$ 1,149	$ 2,006	$ 2,171
Elimination of revenue attributable to multiple locations	(39)	(29)	$ (64)	(60)
Revenue Recognition and Deferred Revenue [Abstract]
Contractual Liabilities			The contract liabilities balances (current and non-current) as of December 31, 2023 and June 30, 2023 are as follows: (Dollars in millions) Balance at June 30, 2023 $ 180 Balance at December 31, 2023 $ 219 Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: $ (114)
Geographical [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue			The following table allocates revenue by the location where the goods were made or the service performed: Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 United States $ 653 $ 734 $ 1,298 $ 1,432 Europe 324 356 599 630 Other 86 88 173 169 Elimination of revenue attributable to multiple locations (39) (29) (64) (60) Total $ 1,024 $ 1,149 $ 2,006 $ 2,171
United States
Disaggregation of Revenue [Line Items]
Net revenue	653	734	$ 1,298	1,432
Europe
Disaggregation of Revenue [Line Items]
Net revenue	324	356	599	630
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 86	$ 88	$ 173	$ 169
Product and Service[Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue			The following tables reflect net revenue for the three and six months ended December 31, 2023 and 2022, by type of activity and reportable segment (in millions): Three Months Ended December 31, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 278 $ 373 $ 651 Development services & clinical supply 160 214 374 Total $ 438 $ 587 $ 1,025 Inter-segment revenue elimination (1) Combined net revenue $ 1,024 Three Months Ended December 31, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 76 $ 364 $ 440 Development services & clinical supply 504 206 710 Total $ 580 $ 570 $ 1,150 Inter-segment revenue elimination (1) Combined net revenue $ 1,149 Six Months Ended December 31, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 560 $ 707 $ 1,267 Development services & clinical supply 326 414 740 Total $ 886 $ 1,121 $ 2,007 Inter-segment revenue elimination (1) Combined net revenue $ 2,006 Six Months Ended December 31, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 171 $ 678 $ 849 Development services & clinical supply 932 391 1,323 Total $ 1,103 $ 1,069 $ 2,172 Inter-segment revenue elimination (1) Combined net revenue $ 2,171

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2023
Goodwill Disclosure [Abstract]
Goodwill - Rollforward	The following table summarizes the changes between June 30, 2023 and December 31, 2023 in the carrying amount of goodwill in total and by segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2023 $ 1,563 $ 1,476 $ 3,039 Foreign currency translation adjustments 2 (3) (1) Impairment (1) (392) (295) (687) Balance at December 31, 2023 $ 1,173 $ 1,178 $ 2,351 (1) Represents gross impairment charges in the period. Accumulated goodwill impairment charges amount to $897 million. Goodwill Impairment Charges As a result of the Consumer Health reporting unit's underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, the Company assessed the current and future economic outlook as of September 30, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified indicators for impairment of the goodwill previously recorded for two of its reporting units. The evaluation began with a qualitative assessment of the Company's Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of $687 million with respect to the Consumer Health and Biomodalities reporting units. While the Company believes the assumptions it used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to the conclusion that an additional impairment was appropriate.

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings (Tables)	3 Months Ended	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings	Long-term obligations and short-term borrowings consisted of the following at December 31, 2023 and June 30, 2023: (Dollars in millions) Maturity December 31, 2023 June 30, 2023 Senior secured credit facilities Term loan facility B-3 (7.471% as of December 31, 2023) February 2028 $ 1,411 $ 1,418 Term loan facility B-4 (8.356% as of December 31, 2023) February 2028 600 — Revolving credit facility November 2027 — 500 5.000% senior notes due 2027 July 2027 500 500 2.375% Euro senior notes due 2028 (1) March 2028 910 904 3.125% senior notes due 2029 February 2029 550 550 3.500% senior notes due 2030 April 2030 650 650 Financing lease obligations 2023 to 2038 398 341 Other obligations (2) 2023 to 2028 36 25 Unamortized discount and debt issuance costs (50) (39) Total debt $ 5,005 $ 4,849 Less: current portion of long-term obligations and other short-term 46 536 Long-term obligations, less current portion $ 4,959 $ 4,313 (1) The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates. (2) The increase in other obligations is primarily associated with $15 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended September 30, 2023.
Fair Value Disclosures [Abstract]
Schedule Of Carrying And Fair Value Of Financial Instruments Table		The carrying amounts and the estimated fair values of the Company’s principal categories of debt as of December 31, 2023 and June 30, 2023 are as follows: December 31, 2023 June 30, 2023 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value 5.000% senior notes due 2027 Level 2 $ 500 $ 499 $ 500 $ 482 2.375% Euro senior notes due 2028 Level 2 910 836 904 784 3.125% senior notes due 2029 Level 2 550 508 550 481 3.500% senior notes due 2030 Level 2 650 598 650 566 Senior secured credit facilities & other Level 2 2,445 2,225 2,284 2,141 Subtotal $ 5,055 $ 4,666 $ 4,888 $ 4,454 Unamortized discount and debt issuance (50) — (39) — Total debt $ 5,005 $ 4,666 $ 4,849 $ 4,454

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three and six months ended December 31, 2023 and 2022, respectively, are as follows: Three Months Ended Six Months Ended (In millions except per share data) 2023 2022 2023 2022 Net (loss) earnings $ (206) $ 81 $ (965) $ 81 Weighted average shares outstanding - basic 182 181 181 180 Weighted average dilutive securities issuable - stock plans — — — 1 Weighted average shares outstanding - diluted 182 181 181 181 (Loss) earnings per share: Basic $ (1.13) $ 0.45 $ (5.31) $ 0.45 Diluted $ (1.13) $ 0.44 $ (5.31) $ 0.45
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	antidilutive effect on the weighted average shares outstanding for the three and six months ended December 31, 2023 and 2022 were not material.

Other Income and Expense (Table

Other Income and Expense (Tables)	6 Months Ended
	Dec. 31, 2023
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The components of other expense (income), net for the three and six months ended December 31, 2023 and 2022 are as follows: Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency losses (gains) (1) $ 4 $ (25) 15 (1) Other — 2 2 3 Total other expense (income), net $ 4 $ (23) $ 17 $ 2 (1) Foreign currency remeasurement gains/losses include both cash and non-cash transactions.

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities Net Investment Hedge Activity (Tables)	6 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance	The following table summarizes net investment hedge activity during the three and six months ended December 31, 2023 and 2022. Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Unrealized foreign exchange loss within other comprehensive income $ (38) $ (85) $ (6) $ (4)
Schedule of Interest Rate Derivatives	A summary of the estimated fair value of the 2021 Rate Swap reported in the consolidated balance sheets is stated in the table below: December 31, 2023 June 30, 2023 (Dollars in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 59 Other long-term assets $ 62

Fair Value Measures and Discl_2

Fair Value Measures and Disclosures (Tables)	6 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at December 31, 2023 and June 30, 2023: (Dollars in millions) Basis of Fair Value Measurement December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 59 $ — $ 59 $ — Trading securities 5 5 — — June 30, 2023 Assets: Interest-rate swap $ 62 $ — $ 62 $ — Trading securities 1 1 — —

Employee Retirement Benefit P_2

Employee Retirement Benefit Plans (Tables)	6 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Components of Company's Net Periodic Benefit Costs	Components of the Company’s net periodic benefit costs are as follows: Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1 $ 1 $ 2 $ 2 Other operating expense: Settlement charges 3 — 3 — Other expense, net: Interest cost 2 2 5 4 Expected return on plan assets (2) (2) (4) (4) Amortization (1) 1 — 1 — Net amount recognized $ 5 $ 1 $ 7 $ 2

Equity and Accumulated Other _2

Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Comprehensive Income (Loss)	Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the three and six months ended December 31, 2023 and 2022 are presented below. Three Months Ended Six Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency translation adjustments: Net investment hedge $ (38) $ (85) $ (6) $ (4) Long-term intercompany loans 14 31 (2) (10) Translation adjustments 73 155 8 (5) Total foreign currency translation adjustment, pretax 49 101 — (19) Tax (benefit) expense 12 (17) 2 (2) Total foreign currency translation adjustment, net of tax $ 37 $ 118 $ (2) $ (17) Net change in derivatives and hedges: Net gain recognized during the period $ (8) $ — $ (2) $ 18 Total derivatives and hedges, pretax (8) — (2) 18 Tax (benefit) expense (1) — — 4 Net change in derivatives and hedges, net of tax $ (7) $ — $ (2) $ 14 Net change in minimum pension liability: Net gain recognized during the period $ 3 $ — $ 3 $ — Total pension liability, pretax 3 — 3 — Tax benefit (1) — (1) — Net change in minimum pension liability, net of tax $ 4 $ — $ 4 $ — Net change in marketable securities: Net gain recognized during the period $ — $ 1 $ — $ 1 Amounts reclassified from accumulated other — 1 — 2 Net change in marketable securities, pretax — 2 — 3 Tax expense — 1 — 1 Net change in marketable securities, net of tax $ — $ 1 $ — $ 2
Schedule of Accumulated Other Comprehensive Income (Loss)	For the three months ended December 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Other Total Balance at September 30, 2023 $ (385) $ (52) $ 50 $ (1) $ (388) Other comprehensive income (loss) before 37 — (7) — 30 Amounts reclassified from accumulated other — 4 — — 4 Net current period other comprehensive income (loss) 37 4 (7) — 34 Balance at December 31, 2023 $ (348) $ (48) $ 43 $ (1) $ (354) (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at September 30, 2022 $ (513) $ (38) $ 41 $ (3) $ (1) $ (514) Other comprehensive income before 118 — — — — 118 Amounts reclassified from accumulated other — — — 1 — 1 Net current period other comprehensive income 118 — — 1 — 119 Balance at December 31, 2022 $ (395) $ (38) $ 41 $ (2) $ (1) $ (395)

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA	(Dollars in millions) Three Months Ended Six Months Ended 2023 2022 2023 2022 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 38 $ 181 $ 87 $ 294 Pharma and Consumer Health 126 135 227 243 Sub-Total $ 164 $ 316 $ 314 $ 537 Reconciling items to net earnings Unallocated costs (1) (159) (52) (936) (139) Depreciation and amortization (121) (103) (233) (202) Interest expense, net (66) (47) (124) (79) Income tax (expense) benefit (24) (33) 14 (36) Net (loss) earnings $ (206) $ 81 $ (965) $ 81 (1) Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Three Months Ended December 31, Six Months Ended 2023 2022 2023 2022 Impairment charges and gain/loss on sale of assets (a) $ (15) $ (1) $ (14) $ 1 Stock-based compensation (16) (10) (35) (29) Restructuring and other special items (b) (83) (33) (106) (42) Goodwill impairment adjustments (charges) (c) 2 — (687) — Pension settlement charges (3) — (3) — Other (expense) income, net (d) (4) 23 (17) (2) Unallocated corporate costs, net (40) (31) (74) (67) Total unallocated costs $ (159) $ (52) $ (936) $ (139) (a) Impairment charges and gain/loss on sale of assets for the three and six months ended December 31, 2023 includes fixed asset impairment charges associated with equipment for a product with significant decline demand in the Company's Biologics segment. (b) Restructuring and other special items during the three months ended December 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. Restructuring and other special items during the three months ended December 31, 2022 include (i) restructuring charges associated with our plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with our Metrics acquisition. Restructuring and other special items for the six months ended December 31, 2022 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. (c) Goodwill impairment charges during the six months ended December 31, 2023 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements. (d) Other expense, net during the three months ended December 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains.
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) December 31, June 30, Assets: Biologics $ 5,363 $ 5,746 Pharma and Consumer Health 4,517 4,867 Corporate and eliminations 108 164 Total assets $ 9,988 $ 10,777

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	6 Months Ended
	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Inventory	Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) December 31, June 30, Raw materials and supplies $ 793 $ 781 Work-in-process 200 186 Total inventories, gross 993 967 Inventory cost adjustment (218) (190) Total inventories $ 775 $ 777
Prepaid and Other Assets	Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) December 31, June 30, Prepaid expenses $ 58 $ 53 Short-term contract assets 478 399 Spare parts supplies 27 24 Prepaid income tax 75 77 Non-U.S. value-added tax 45 38 Other current assets 40 42 Total prepaid expenses and other $ 723 $ 633
Other Accrued Liabilities	Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) December 31, June 30, Contract liabilities $ 214 $ 167 Accrued employee-related expenses 136 160 Accrued expenses 141 134 Operating lease liabilities 9 11 Restructuring accrual 16 19 Accrued interest 39 35 Accrued income tax 28 44 Total other accrued liabilities $ 583 $ 570

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Research and Development Expense [Abstract]
Research and Development Costs		Research and Development Costs
Research and Development Expense	$ 4	$ 8	$ 9

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies Concentrations of Credit Risk and Major Customers (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2023 Rate	Dec. 31, 2022	Dec. 31, 2022	Jun. 30, 2023 Rate
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Percentage, trade receivables and current contract asset values, Net	27%			20%
Segment Reporting, Disclosure of Major Customers	16	13%	11%
Segment Reporting, Disclosure of Major Customer		1,000%	1,000%

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Polices Depreciation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Depreciation, Depletion and Amortization [Abstract]
Depreciation, Depletion, and Amortization			Depreciation Depreciation expense was $88 million and $69 million for the three months ended December 31, 2023 and 2022, respectively. Depreciation expense was $166 million and $135 million for the six months ended December 31, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. Amortization
Depreciation Cost	$ 88	$ 69	$ 166	$ 135

Accounting Changes and Error _2

Accounting Changes and Error Corrections (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities						$ 646
Total current liabilities	$ 1,036		$ 1,036			1,098	$ 1,530
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities						646
Total current liabilities	1,036		1,036			1,098	1,530
Total liabilities	6,301		6,301			5,733	6,166
Accumulated deficit	(703)		(703)			518	262
Equity, Attributable to Parent	3,687		3,687			4,775	4,611
Prepaid expenses and other	723		723			626	633
Assets, Current	2,570		2,570			2,917	2,692
Deferred Income Tax Assets, Net	55		55				55
Assets	9,988		9,988			10,508	10,777
Liabilities and Equity	9,988		9,988			10,508	10,777
Net revenue	1,024	$ 1,149	2,006	$ 2,171
Gross margin	171	387	340	645
Operating earnings	(112)	138	(838)	198
Deferred Tax Liabilities, Gross	50		50				76
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(182)	114	(979)	117
Income tax expense(benefit)	24	33	(14)	36
Net earnings/(loss)	$ (206)	$ 81	$ (965)	$ 81	$ (965)
Earnings Per Share, Basic	$ (1.13)	$ 0.45	$ (5.31)	$ 0.45
Earnings Per Share, Diluted	$ (1.13)	$ 0.44	$ (5.31)	$ 0.45
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (172)	$ 200	$ (965)	$ 80
Net earnings/(loss)			(965)	81
Provision/(benefit) for deferred income taxes			27	(13)
Other assets/accrued liabilities, net — current and non-current			(85)	(181)
Net cash provided by operating activities			42	122
Net Cash Provided by (Used in) Investing Activities			(179)	(724)
Net Cash Provided by (Used in) Financing Activities			84	597
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect			(51)	(7)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	229	442	229	442			280	$ 449
Share issuances related to stock-based compensation			35	29
Cash paid, in lieu of equity, for tax withholding		2
Proceeds from Stock Options Exercised			(1)	(1)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	2	4			5
Other Comprehensive Income (Loss), Net of Tax	34	119	0	(1)	$ 0
Inventories	775		775				777
Cost of sales	853	762	1,666	1,526
Deferred Tax Liabilities, Tax Deferred Income						197
Total liabilities	6,301		6,301			5,733	6,166
Accumulated deficit	(703)		(703)			518	262
Equity, Attributable to Parent	3,687		3,687			4,775	4,611
Inventories	775		775				777
Biologics
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	5,363		5,363				5,746
Biologics | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	278	76	560	171
Biologics | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	160	504	326	932
PharmaConsumerHealth
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	4,517		4,517				4,867
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	373	364	707	678
PharmaConsumerHealth | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	214	206	414	391
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	651	440	1,267	849
Total Catalent before inter-segment revenue elimination | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 374	$ 710	$ 740	$ 1,323
Previously Reported
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities						620
Total current liabilities						1,072
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities						620
Total current liabilities						1,072
Total liabilities						5,712
Accumulated deficit						538
Equity, Attributable to Parent						4,795
Prepaid expenses and other						625
Assets, Current						2,916
Assets						10,507
Liabilities and Equity							10,507
Deferred Tax Liabilities, Gross						202
Total liabilities						5,712
Accumulated deficit						538
Equity, Attributable to Parent						4,795
Restatement Adjustment
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities						26
Total current liabilities						26
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities						26
Total current liabilities						26
Total liabilities						21
Accumulated deficit						(20)
Equity, Attributable to Parent						(20)
Prepaid expenses and other						1
Assets, Current						1
Assets						1
Liabilities and Equity							$ 1
Total liabilities						21
Accumulated deficit						(20)
Equity, Attributable to Parent						(20)
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred Tax Liabilities, Gross						$ (5)

Revenue from Contract with Cust

Revenue from Contract with Customer (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,024,000,000	$ 1,149,000,000	$ 2,006,000,000	$ 2,171,000,000
Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	1,024,000,000
Operating Segments Excluding Intersegment Elimination
Disaggregation of Revenue [Line Items]
Net revenue	1,025,000,000	1,150,000,000	2,007,000,000	2,172,000,000
Biologics | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	438,000,000	580,000,000	886,000,000	1,103,000,000
PharmaConsumerHealth | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	587,000,000	570,000,000	1,121,000,000	1,069,000,000
Total Catalent Segment | Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Net revenue	(1,000,000)	(1,000,000)	(1,000,000)	(1,000,000)
Manufacturing & Commercial Product Supply | Biologics
Disaggregation of Revenue [Line Items]
Net revenue	278,000,000	76,000,000	560,000,000	171,000,000
Manufacturing & Commercial Product Supply | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	373,000,000	364,000,000	707,000,000	678,000,000
Development Services | Biologics
Disaggregation of Revenue [Line Items]
Net revenue	160,000,000	504,000,000	326,000,000	932,000,000
Development Services | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	$ 214,000,000	$ 206,000,000	$ 414,000,000	$ 391,000,000

Revenue Recognition Disaggregat

Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,024,000,000	$ 1,149,000,000	$ 2,006,000,000	$ 2,171,000,000
Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	1,024,000,000
Operating Segments Excluding Intersegment Elimination
Disaggregation of Revenue [Line Items]
Net revenue	1,025,000,000	$ 1,150,000,000	2,007,000,000	$ 2,172,000,000
Greater Than One Year Member [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months		36%		36%
Biologics | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	438,000,000	$ 580,000,000	886,000,000	$ 1,103,000,000
Biologics | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	278,000,000	76,000,000	560,000,000	171,000,000
Biologics | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	160,000,000	504,000,000	326,000,000	932,000,000
PharmaConsumerHealth | Operating Segments
Disaggregation of Revenue [Line Items]
Net revenue	587,000,000	570,000,000	1,121,000,000	1,069,000,000
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	373,000,000	364,000,000	707,000,000	678,000,000
PharmaConsumerHealth | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	214,000,000	206,000,000	414,000,000	391,000,000
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	651,000,000	440,000,000	1,267,000,000	849,000,000
Total Catalent before inter-segment revenue elimination | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	374,000,000	710,000,000	740,000,000	1,323,000,000
Total Catalent Segment | Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Net revenue	$ (1,000,000)	$ (1,000,000)	$ (1,000,000)	$ (1,000,000)

Revenue Recognition Disaggreg_2

Revenue Recognition Disaggregation of Revenue by Geography (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Elimination of revenue attributable to multiple locations	$ (39)	$ (29)	$ (64)	$ (60)
Net revenue	1,024	1,149	2,006	2,171
United States
Disaggregation of Revenue [Line Items]
Net revenue	653	734	1,298	1,432
Europe
Disaggregation of Revenue [Line Items]
Net revenue	324	356	599	630
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 86	$ 88	$ 173	$ 169

Revenue Recognition Contractual

Revenue Recognition Contractual Liabilities (Details) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]
Contract with Customer, Liability	$ 219	$ 180
Contract with Customer, Liability, Revenue Recognized	(114)
Revenue, Remaining Performance Obligation, Amount	$ 692

Revenue Recognition Contractu_2

Revenue Recognition Contractual Assets (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
Text Block [Abstract]
Contract with Customer, Asset, Purchase	$ 495,000,000	$ 417,000,000
Increase (Decrease) in Contract with Customer, Asset	78,000,000
Increase (Decrease) in Contract with Customer, Asset percent	$ 0.19

Business Combinations Acquisiti

Business Combinations Acquisition Purchase Agreement (Details) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	$ 0	$ 474

Business Combinations Net Asset

Business Combinations Net Assets Acquired (Details) - USD ($) $ in Millions		6 Months Ended
	Oct. 01, 2022	Dec. 31, 2023	Dec. 31, 2022
Net Assets Acquired from Business Combinations
Payments to Acquire Businesses, Net of Cash Acquired		$ 0	$ 474
Payments to Acquire Businesses, Net of Cash Acquired		$ 0	$ 474
Metrics
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 195
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	52
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	15
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	474
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	12
Business Combination, Consideration Transferred	474
Goodwill, Acquired During Period	219
Metrics | Customer Relationships [Member]
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 52
Weighted Average Life	12 years

Goodwill - Rollforward (Detail)

Goodwill - Rollforward (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Beginning balance			$ 3,039,000,000
Foreign currency translation adjustments			(1,000,000)
Ending balance	$ 2,351,000,000		$ 2,351,000,000
Goodwill Input, Discount Rate Minimum, Percentage	10%		10%
Net revenue	$ 1,024,000,000	$ 1,149,000,000	$ 2,006,000,000	$ 2,171,000,000
Goodwill Inputs Long Term Revenue Growth Rate, Percentage	3.50%		3.50%
Goodwill Input, Discount Rate Minimum, Percentage	10%		10%
Goodwill Input Discount Rate Minimum, Percentage	9%		9%
Goodwill, Impairment Loss	$ (2,000,000)	0	$ (687,000,000)	0
Goodwill, Impaired, Accumulated Impairment Loss	897,000,000		897,000,000
Biologics
Goodwill [Roll Forward]
Beginning balance			1,563,000,000
Foreign currency translation adjustments			2,000,000
Ending balance	1,173,000,000		1,173,000,000
Goodwill, Impairment Loss			(392,000,000)
Biologics | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	278,000,000	76,000,000	560,000,000	171,000,000
Biologics | Development Services
Goodwill [Roll Forward]
Net revenue	160,000,000	504,000,000	326,000,000	932,000,000
PharmaConsumerHealth
Goodwill [Roll Forward]
Beginning balance			1,476,000,000
Foreign currency translation adjustments			(3,000,000)
Ending balance	1,178,000,000		1,178,000,000
Goodwill, Impairment Loss	(295,000,000)	0	(687,000,000)	0
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	373,000,000	364,000,000	707,000,000	678,000,000
PharmaConsumerHealth | Development Services
Goodwill [Roll Forward]
Net revenue	214,000,000	206,000,000	414,000,000	391,000,000
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	651,000,000	440,000,000	1,267,000,000	849,000,000
Total Catalent before inter-segment revenue elimination | Development Services
Goodwill [Roll Forward]
Net revenue	$ 374,000,000	$ 710,000,000	$ 740,000,000	$ 1,323,000,000

Other Intangibles, Net (Detail)

Other Intangibles, Net (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2022
Intangible Assets Disclosure [Abstract]
Amortization expense	$ 33	$ 34	$ 67

Long-Term Obligations and Oth_2

Long-Term Obligations and Other Short-Term Borrowings - Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings (Detail) - USD ($) $ in Millions		3 Months Ended
		Dec. 31, 2023	Jun. 30, 2023
Schedule Of Debt [Line Items]
Total long-term debt		$ 5,005	$ 4,849
Debt, Current		46	536
Long-term obligations, less current portion		4,959	4,313
Debt Instrument, Unused Borrowing Capacity, Amount		1,090
Letters of Credit Outstanding, Amount		6
Sale and Leaseback Transaction, Gain (Loss), Net		15
Term loan facility B-3 U.S. dollar-denominated
Schedule Of Debt [Line Items]
Total long-term debt		1,411	1,418
Revolving Credit Facility - Two
Schedule Of Debt [Line Items]
Total long-term debt		0	500
Capital lease obligations
Schedule Of Debt [Line Items]
Total long-term debt		398	341
Other obligations
Schedule Of Debt [Line Items]
Total long-term debt		36	25
Term Loan Four Facility Dollar Denominated
Schedule Of Debt [Line Items]
Total long-term debt		$ 600
Debt Instrument, Interest Rate, Stated Percentage		200%
Estimate of Fair Value Measurement [Member]
Schedule Of Debt [Line Items]
Total long-term debt		$ 4,666	4,454
Debt Instrument, Fair Value Disclosure		4,666	4,454
Estimate of Fair Value Measurement [Member] | Debt Issuance Costs
Schedule Of Debt [Line Items]
Total long-term debt		0	0
Carrying Value [Member]
Schedule Of Debt [Line Items]
Total long-term debt		5,005	4,849
Debt Instrument, Fair Value Disclosure		5,055	4,888
Carrying Value [Member] | Debt Issuance Costs
Schedule Of Debt [Line Items]
Total long-term debt		50	39
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		499	482
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		836	784
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		508	481
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 3.500% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		598	566
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		500	500
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	[1]	910	904
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		550	550
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 3.500% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		$ 650	$ 650
[1]The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates. (2) The increase in other obligations is primarily associated with $15 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended September 30, 2023.

Long-Term Obligations and Oth_3

Long-Term Obligations and Other Short-Term Borrowings Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Total long-term debt	$ 5,005	$ 4,849
Term loan facility B-3 U.S. dollar-denominated
Debt Instrument [Line Items]
Total long-term debt	1,411	1,418
Revolving Credit Facility - Two
Debt Instrument [Line Items]
Total long-term debt	0	$ 500
Term Loan Four Facility Dollar Denominated
Debt Instrument [Line Items]
Total long-term debt	$ 600
Debt Instrument, Interest Rate, Stated Percentage	200%
Stated Percentage, Quarterly Amortization of Principal	100%
Term Loan Four Facility Dollar Denominated | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	300%
Term Loan Four Facility Dollar Denominated | Secured Overnight Financing Rate (SOFR) | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	50%
Deferred purchase consideration
Debt Instrument [Line Items]
Stated Percentage, Draw Outsanding	3,000%

Long-Term Obligations and Oth_4

Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details) - USD ($) $ in Millions		Dec. 31, 2023	Jun. 30, 2023
Fair Value Measurements Of Financial Instruments [Line Items]
Total long-term debt		$ 5,005	$ 4,849
Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		4,666	4,454
Total long-term debt		4,666	4,454
Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		5,055	4,888
Total long-term debt		5,005	4,849
Term loan facility B-3 U.S. dollar-denominated
Fair Value Measurements Of Financial Instruments [Line Items]
Total long-term debt		1,411	1,418
U.S Dollar-denominated 5.00% Senior Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		499	482
U.S Dollar-denominated 5.00% Senior Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		500	500
2.375% Senior Euro Denominated Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		836	784
2.375% Senior Euro Denominated Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	[1]	910	904
3.125% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		508	481
3.125% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		550	550
Senior Secured Credit Facilities & Other [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		2,225	2,141
Senior Secured Credit Facilities & Other [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		$ 2,445	$ 2,284
[1]The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates. (2) The increase in other obligations is primarily associated with $15 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended September 30, 2023.

Earnings Per Share Earnings Per

Earnings Per Share Earnings Per Share - Additional Details (Details) - $ / shares	Feb. 05, 2024	Dec. 31, 2023	Jun. 30, 2023
Earnings Per Share [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Earnings Per Share [Abstract]
Net earnings/(loss)	$ (206)	$ 81	$ (965)	$ 81	$ (965)
Weighted Average Number of Shares Outstanding, Basic	182	181	181	180
Dilutive securities issuable-stock plans	0	0	0	1
Total weighted average diluted shares outstanding	182	181	181	181
Earnings Per Share, Basic	$ (1.13)	$ 0.45	$ (5.31)	$ 0.45
Earnings Per Share, Diluted	$ (1.13)	$ 0.44	$ (5.31)	$ 0.45

Other Income and Expense (Detai

Other Income and Expense (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Other Income and Expenses [Abstract]
Foreign Currency (gains) and losses	[1]	$ 4	$ (25)	$ 15	$ (1)
Other	[2]	0	2	2	3
Other (income)/expense, net	[3]	$ 4	$ (23)	$ 17	$ 2
[1]Foreign currency remeasurement gains/losses include both cash and non-cash transactions.[2]

Restructuring and Other Costs (

Restructuring and Other Costs (Details)	3 Months Ended			6 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($) employees	Dec. 31, 2022 USD ($)	Jan. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)
Restructuring and Related Activities [Abstract]
Severance Costs	$ 10,000,000	$ 12,000,000		$ 12,000,000	$ 14,000,000
Business Exit Costs	7,000,000	11,000,000	$ 13,000,000	7,000,000
Restructuring and other	17,000,000	23,000,000		$ 19,000,000	27,000,000
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost						$ 25
Restructuring and Related Cost [Abstract]
Restructuring and Related Cost, Number of Positions Eliminated | employees				300
Restructuring and other	17,000,000	23,000,000		$ 19,000,000	27,000,000
Restructuring Reserve	16,000,000			16,000,000			$ 19,000,000
Restructuring and Related Cost, Incurred Cost				12,000,000
Payments for Restructuring				(15,000,000)
Severance Costs	10,000,000	12,000,000		12,000,000	14,000,000
Biologics
Restructuring and Related Activities [Abstract]
Restructuring and other	6,000,000	18,000,000		7,000,000	18,000,000
Restructuring and Related Cost [Abstract]
Restructuring and other	6,000,000	18,000,000		7,000,000	18,000,000
PharmaConsumerHealth
Restructuring and Related Activities [Abstract]
Restructuring and other	10,000,000	1,000,000		11,000,000	4,000,000
Restructuring and Related Cost [Abstract]
Restructuring and other	10,000,000	1,000,000		11,000,000	4,000,000
Corporate and Eliminations [Member]
Restructuring and Related Activities [Abstract]
Restructuring and other	1,000,000	4,000,000		1,000,000	5,000,000
Restructuring and Related Cost [Abstract]
Restructuring and other	$ 1,000,000	$ 4,000,000		$ 1,000,000	$ 5,000,000

Restructuring and Other Costs I

Restructuring and Other Costs Individual Site (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost					$ 25
Restructuring and other	$ 17,000,000	$ 23,000,000	$ 19,000,000	$ 27,000,000

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023	Feb. 28, 2021
Derivative [Line Items]
Total long-term debt	$ 5,005		$ 5,005		$ 4,849
Unrealized foreign exchange gain/(loss) within other comprehensive income	(38)	$ (85)	(6)	$ (4)
Net accumulated gain related to investment hedges			91
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	2
Interest Rate Cash Flow Hedge Liability at Fair Value					62
Carrying Value [Member]
Derivative [Line Items]
Total long-term debt	5,005		5,005		4,849
Debt Instrument, Fair Value Disclosure	5,055		5,055		$ 4,888
Euro Denominated Debt Outstanding [Member]
Derivative [Line Items]
Total long-term debt	910		910
U.S. Denominated Term Loan [Member]
Derivative [Line Items]
Total Debt, U.S Denominated Term Loan	500		500
Debt Instrument, Interest Rate, Effective Percentage					0.9431%	0.9985%
3.500% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Derivative [Line Items]
Debt Instrument, Fair Value Disclosure	$ 650		$ 650		$ 650

Fair value measurement recurrin

Fair value measurement recurring basis (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Trading Securities at Fair Value	$ 5	$ 1
Interest Rate Cash Flow Hedge Asset at Fair Value	59	62
Interest Rate Cash Flow Hedge Liability at Fair Value		62
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Trading Securities at Fair Value	5	1
Interest Rate Cash Flow Hedge Asset at Fair Value	59	62
Interest Rate Cash Flow Hedge Liability at Fair Value		62
Fair Value, Inputs, Level 1 [Member]
Fair Value Disclosures [Abstract]
Trading Securities at Fair Value	5	1
Interest Rate Cash Flow Hedge Asset at Fair Value	0	0
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Trading Securities at Fair Value	5	1
Interest Rate Cash Flow Hedge Asset at Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Disclosures [Abstract]
Trading Securities at Fair Value	0	0
Interest Rate Cash Flow Hedge Asset at Fair Value	59	62
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Trading Securities at Fair Value	0	0
Interest Rate Cash Flow Hedge Asset at Fair Value	59	62
Fair Value, Inputs, Level 3 [Member]
Fair Value Disclosures [Abstract]
Trading Securities at Fair Value	0	0
Interest Rate Cash Flow Hedge Asset at Fair Value	0	0
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Trading Securities at Fair Value	0	0
Interest Rate Cash Flow Hedge Asset at Fair Value	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued					$ 4
Income tax expense(benefit)	$ 24	$ 33	$ (14)	$ 36
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (182)	$ 114	$ (979)	$ 117

Employee Retirement Benefit P_3

Employee Retirement Benefit Plans - Components of Company's Net Periodic Benefit Costs (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Components of net periodic benefit cost:
Service cost		$ 1,000,000	$ 1,000,000	$ 2,000,000	$ 2,000,000
Interest cost		2,000,000	2,000,000	5,000,000	4,000,000
Expected return on plan assets		(2,000,000)	(2,000,000)	(4,000,000)	(4,000,000)
Amortization		1,000,000	0	1,000,000	0
Net amount recognized		5,000,000	1,000,000	7,000,000	2,000,000
Estimated discounted value of future employer contributions		44,000,000		44,000,000		$ 38,000,000
Estimated annual cash contribution		2,000,000	$ 2,000,000	2,000,000	$ 2,000,000
Defined Benefit Plan, Plan Assets, Payment for Settlement		7
Debtor Reorganization Items, Pension and Other Postretirement Related Charges		3,000,000		$ 3,000,000
Pension Settlement Charges	$ 12	$ 3,000,000
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate		450%		450%

Equity and Accumulated Other _3

Equity and Accumulated Other Comprehensive Income (Loss) - Equity (Details) - $ / shares	Dec. 31, 2023	Jun. 30, 2023
Equity [Abstract]
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Outstanding	0	0
Auction Market Preferred Securities, Stock Series [Line Items]
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Issued	0	0

Equity and Accumulated Other _4

Equity and Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Foreign currency translation adjustments:
Net investment hedge	$ (38)	$ (85)	$ (6)	$ (4)
Long-term intercompany loans	14	31	(2)	(10)
Translation adjustments	73	155	8	(5)
Total foreign currency translation adjustment, pretax	49	101	0	(19)
Tax expense/(benefit)	12	(17)	2	(2)
Total foreign currency translation adjustment, net of tax	37	118	(2)	(17)
Net change in derivatives and hedges
Net loss recognized during the period	(8)	0	(2)	18
Total derivatives and hedges, pretax	(8)	0	(2)	18
Tax expense/(benefit)	(1)	0	0	4
Net change in derivatives and hedges, net of tax	(7)	0	(2)	14
Net change in minimum pension liability
Net gain/(loss) recognized during the period	3	0	3	0
Total pension liability, pretax	3	0	3	0
Tax expense/(benefit)	(1)	0	(1)	0
Pension and other post-retirement adjustments	4	0	4	0
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]
Available-for-sale Securities, Gross Realized Losses	0	1	0	1
Total available for sale investment, pretax	0	2	0	3
Tax expense/(benefit)		0	0	1
Available for sale investments	0	1	0	2
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income/(loss) before reclassifications	$ 30	$ 118	$ (4)	$ (3)

Equity and Accumulated Other _5

Equity and Accumulated Other Comprehensive Income (Loss) - Rollforward (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ (388)	$ (514)	$ (354)	$ (394)	$ (354)
Other comprehensive income/(loss) before reclassifications	30	118	(4)	(3)
Amounts reclassified from accumulated other comprehensive income/(loss)	4	(1)	(4)	(2)
Total foreign currency translation adjustment, net of tax	37	118	(2)	(17)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	4	0	4	0
Net change in derivatives and hedges, net of tax	(7)	0	(2)	14
Other Comprehensive Income, Other, Net of Tax	34	119	0	(1)
Available for sale investments	0	1	0	2
Other comprehensive income/(loss), net of tax	34	119	0	(1)	0
Ending Balance	(354)	(395)	(354)	(395)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(385)	(513)	(346)	(378)	(346)
Other comprehensive income/(loss) before reclassifications	37	118	(2)	(17)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Total foreign currency translation adjustment, net of tax		118
Ending Balance	(348)	(395)	(348)	(395)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(52)	(38)	(52)	(38)	(52)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	4	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	4	0	(4)
Ending Balance	(48)	(38)	(48)	(38)
AOCI, Derivative Qualifying as Hedge, Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	50	41	45	27	45
Other comprehensive income/(loss) before reclassifications	(7)	0		14
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Net change in derivatives and hedges, net of tax		0
Ending Balance	43	41	43	41
ACOI, Accumulated Gain (Loss), Marketable Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance		(3)		(4)
Other comprehensive income/(loss) before reclassifications		0
Amounts reclassified from accumulated other comprehensive income/(loss)	0	1	0	2
Net change in derivatives and hedges, net of tax	(7)
Available for sale investments		1	0	2
Ending Balance		(2)		(2)
Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(1)	(1)	(1)		$ (1)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Other Comprehensive Income, Other, Net of Tax	0
Ending Balance	$ (1)	$ (1)	$ (1)	$ (1)

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Feb. 05, 2024
Commitments and Contingencies Disclosure [Abstract]
Estimated Fire Damage Loss	$ 9
Business Combination, Termination Fee		$ 345

Segment Information - Net Reven

Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		$ 1,024	$ 1,149	$ 2,006	$ 2,171
Segment Reporting Information Unallocated Expense	[1]	(159)	(52)	(936)	(139)
Biologics
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		38	181	87	294
PharmaConsumerHealth
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		126	135	227	243
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		$ 164	$ 316	$ 314	$ 537
[1]Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information, EBITDA, Re

Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets		$ 15	$ 1	$ 14	$ (1)
Stock-based compensation		16	10	35	29
Restructuring And Other Special Items	[1]	83	33	106	42
Debtor Reorganization Items, Pension and Other Postretirement Related Charges		(3)		(3)
Other (income)/expense, net	[2]	(4)	23	(17)	(2)
Non Allocated Corporate Costs Net		40	31	74	67
Segment Reporting Information Unallocated Expense	[3]	159	52	936	139
Goodwill, Impairment Loss		$ 2	$ 0	$ 687	$ 0
[1]Restructuring and other special items during the three months ended December 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. Restructuring and other special items during the three months ended December 31, 2022 include (i) restructuring charges associated with our plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with our Metrics acquisition. Restructuring and other special items for the six months ended December 31, 2022 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements. (c) Goodwill impairment charges during the six months ended December 31, 2023 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements.

Segment Information - Reconcili

Segment Information - Reconciliation of Earnings / (Loss) from Continuing Operations to Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting Information Unallocated Expense	[1]	$ 159	$ 52	$ 936	$ 139
Depreciation and amortization		121	103	233	202
Interest expense, net		66	47	124	79
Income tax expense(benefit)		24	33	(14)	36
Earnings/(loss) from continuing operations		$ (206)	$ 81	$ (965)	$ 81
[1]Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information - Total Ass

Segment Information - Total Assets for Each Segment and Reconciling in Consolidated Financial Statements (Detail) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 10,508	$ 9,988	$ 10,777
Biologics
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		5,363	5,746
PharmaConsumerHealth
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		4,517	4,867
Corporate and Eliminations [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		$ 108	$ 164

Segment Information - Major Cus

Segment Information - Major Customers (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting, Disclosure of Major Customers	16	13%	11%

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Inventory (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Inventory, Net [Abstract]
Raw materials and supplies	$ 793	$ 781
Work-in-process	200	186
Total inventories, gross	993	967
Inventory cost adjustment	(218)	(190)
Inventories	$ 775	$ 777

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses		$ 58	$ 53
Contract with Customer, Asset, Net, Current		478	399
Spare parts supplies		27	24
Prepaid income tax		75	77
Non-U.S. value added tax		45	38
Other current assets		40	42
Prepaid expenses and other	$ 626	$ 723	$ 633

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Accrued employee-related expenses	$ 136	$ 160
Accrued Operating Lease, Liabilities	9	11
Restructuring accrual	16	19
Accrued interest	39	35
Contract liability	214	167
Accrued income tax	28	44
Other accrued liabilities and expenses	141	134
Other accrued liabilities	$ 583	$ 570

Allowance for Credit Loss (Deta

Allowance for Credit Loss (Details) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
Text Block [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 42	$ 46
Accounts Receivable, Credit Loss Expense (Reversal)	$ (4)

Subsequent Events (Details)

Subsequent Events (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Jun. 30, 2024 USD ($)	Feb. 05, 2024 USD ($) $ / shares	Jan. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Subsequent Event
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued									$ 4,000,000
Assets	$ 9,988,000,000		$ 9,988,000,000		$ 10,508,000,000				10,777,000,000
Other comprehensive income/(loss) before reclassifications	30,000,000	$ 118,000,000	(4,000,000)	$ (3,000,000)
Foreign currency translation adjustments	37,000,000	118,000,000	(2,000,000)	(17,000,000)
Net change in derivatives and hedges, net of tax	(7,000,000)	0	(2,000,000)	14,000,000
Available for sale investments	0	1,000,000	0	2,000,000
Other Comprehensive Income, Other, Net of Tax	34,000,000	119,000,000	0	(1,000,000)
Accumulated other comprehensive income/(loss)	(354,000,000)	(395,000,000)	(354,000,000)	(395,000,000)				$ (388,000,000)	$ (354,000,000)	$ (514,000,000)	$ (394,000,000)
Amounts reclassified from accumulated other comprehensive income/(loss)	4,000,000	(1,000,000)	(4,000,000)	(2,000,000)
Pension and other post-retirement adjustments	$ 4,000,000	0	4,000,000	0
Tax expense/(benefit)		0	$ 0	1,000,000
Restructuring and Related Cost, Expected Cost							$ 25
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01		$ 0.01			$ 0.01			$ 0.01
Business Combination, Termination Fee						$ 345
Merger Agreement
Subsequent Event
Business Combination, Purchase Price per Share | $ / shares						$ 63.5
Business Combination, Enterprise Value						16,500,000,000
Accumulated Translation Adjustment [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications	$ 37,000,000	118,000,000	$ (2,000,000)	(17,000,000)
Foreign currency translation adjustments		118,000,000
Accumulated other comprehensive income/(loss)	(348,000,000)	(395,000,000)	(348,000,000)	(395,000,000)				(385,000,000)	$ (346,000,000)	(513,000,000)	(378,000,000)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
AOCI, Derivative Qualifying as Hedge, Parent [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications	(7,000,000)	0		14,000,000
Net change in derivatives and hedges, net of tax		0
Accumulated other comprehensive income/(loss)	43,000,000	41,000,000	43,000,000	41,000,000				50,000,000	45,000,000	41,000,000	27,000,000
Amounts reclassified from accumulated other comprehensive income/(loss)	0
ACOI, Accumulated Gain (Loss), Marketable Securities [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		0
Net change in derivatives and hedges, net of tax	(7,000,000)
Available for sale investments		1,000,000	0	2,000,000
Accumulated other comprehensive income/(loss)		(2,000,000)		(2,000,000)						(3,000,000)	(4,000,000)
Amounts reclassified from accumulated other comprehensive income/(loss)	0	1,000,000	0	2,000,000
Accumulated Defined Benefit Plans Adjustment [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications	0
Accumulated other comprehensive income/(loss)	(48,000,000)	(38,000,000)	(48,000,000)	(38,000,000)				(52,000,000)	(52,000,000)	(38,000,000)	$ (38,000,000)
Amounts reclassified from accumulated other comprehensive income/(loss)	4,000,000	0
Pension and other post-retirement adjustments	4,000,000	0	(4,000,000)
Available-for-sale Securities [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications	0
Other Comprehensive Income, Other, Net of Tax	0
Accumulated other comprehensive income/(loss)	(1,000,000)	(1,000,000)	(1,000,000)	(1,000,000)				$ (1,000,000)	(1,000,000)	$ (1,000,000)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
PharmaConsumerHealth
Subsequent Event
Segment EBITDA	126,000,000	$ 135,000,000	227,000,000	$ 243,000,000
Assets	$ 4,517,000,000		$ 4,517,000,000						$ 4,867,000,000

Uncategorized Items - ctlt-2023

Label	Element	Value
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	$ 35,000,000
Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash	us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash	3,000,000
Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4,892,000,000
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1,000,000
AOCI Attributable to Parent [Member]
Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(395,000,000)
Other Comprehensive Income (Loss), Net of Tax	us-gaap_OtherComprehensiveIncomeLossNetOfTax	0
Additional Paid-in Capital [Member]
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35,000,000
Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4,686,000,000
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5,000,000
Proceeds from Tax Withholding Obligations	ctlt_ProceedsFromTaxWithholdingObligations	(1,000,000)
Retained Earnings [Member]
Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	599,000,000
Net Income (Loss)	us-gaap_NetIncomeLoss	(965,000,000)
Common Stock [Member]
Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ 2,000,000
Common Stock, Shares, Outstanding	us-gaap_CommonStockSharesOutstanding	179,988,000,000
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	395,000,000